Cell Therapies for Blood Cancers: CAR-T, TCR, TIL, and Donor Cells Are Not the Same

"Cell therapy" is a category, not a treatment

The phrase covers products built from different cells, aimed at different targets, and used in different ways. Coverage that treats them as one thing will mislead you.

This page explains federal sources. It is not medical advice and does not suggest a test or treatment.

What NCI groups together, and how

NCI describes T-cell transfer therapy as a type of immunotherapy that makes your own immune cells better able to attack cancer. It is also called adoptive cell therapy.

NCI names two main types.

CAR T-cell therapy. Your T cells are changed in the laboratory so they produce a chimeric antigen receptor, or CAR. That receptor lets them attach to specific proteins on the surface of cancer cells. NCI reports six CAR T-cell therapies approved by FDA for blood cancers.

TIL therapy. This uses tumor-infiltrating lymphocytes, T cells found inside your tumor. Doctors test them in the laboratory to see which best recognize the tumor cells, then grow those to large numbers. The reasoning is that cells already inside the tumor have shown they can recognize it, but there may be too few of them. A TIL therapy called lifileucel has been approved by FDA for melanoma. NCI notes it has produced promising findings in some other cancers, but remains experimental for those.

Both share the same shape: collect your cells, grow large numbers in the laboratory, return them through a vein. NCI says growing them takes two to eight weeks, and that chemotherapy, and sometimes radiation, is given first to reduce your existing immune cells.

Where a stem cell transplant fits

This is the distinction most often blurred, and it is a large one.

NCI explains that stem cell transplants restore blood stem cells in people whose own have been destroyed by high doses of chemotherapy or radiation. They are used most often for cancers of the blood cells, such as leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes.

Then comes the key sentence. NCI states that stem cell transplants do not usually work against cancer directly. They restore the body's ability to make new blood cells after treatment strong enough to destroy cancer cells.

There is one exception NCI names. In leukemia, a transplant using a donor's stem cells may work against the cancer directly, through an effect called graft-versus-tumor or graft-versus-leukemia. White blood cells from the donor attack cancer cells that remain.

So the purpose differs. One approach supplies fighters. The other rebuilds the blood system. Our comparison of transplant versus CAR T-cell therapy sets them side by side, and what a stem cell transplant is covers the procedure.

Count from enrollment, not from infusion

Here is a reporting problem worth watching for. Not everyone who enrolls in a cell therapy trial receives the cells. Manufacturing can fail. People can become too unwell during the weeks of waiting.

A response rate calculated only among those who reached infusion looks better than the treatment really is. A good report follows people from enrollment through collection, manufacturing, infusion, and long-term follow-up, and explains what happened to those who dropped out along the way.

Long-term monitoring is part of the treatment

In November 2023, FDA announced it was investigating more than 20 instances of second cancers, specifically T-cell lymphomas, in people treated with CAR T-cell therapies. In several of these, genes used to make the treatment were present in the new lymphoma.

Two reports published in June 2024 examined this closely, and they did not agree. One studied more than 700 people treated at a single center over nine years. Of 25 second cancers, only one was a T-cell lymphoma, no CAR genes were found in it, and the researchers concluded the therapy had not directly caused it. The other was a single case, a person who developed a T-cell lymphoma about five months after CAR T-cell therapy for multiple myeloma. There, a CAR gene was found in the lymphoma cells along with other cancer-causing changes, and the team concluded the treatment probably contributed.

NCI explains why this surfaced only recently. Rare problems do not produce a signal until a treatment has been used in many people. More than 34,000 people have now received CAR T-cell therapy. Our page on CAR T-cell therapy covers the treatment itself.

What the category label does not tell you

• "Cell therapy" does not name one interchangeable treatment.
• Approval for one blood cancer does not extend to another.
• Manufacturing time, prior treatment, infection risk, and immune side effects all differ by product.
• Results from one product cannot be moved onto another.

Questions about a cell therapy story

• Whose cells are used, and how are they changed?
• What target does the therapy recognize?
• Is this approved for this cancer, or available only in a trial?
• How many enrolled people actually received the cells?
• What short-term and long-term monitoring is required?

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.